araag2/HINT huggingface dataset:
Clinical trial NCT01061723 (phase 2, status: completed)
Conditions: ankylosing spondylitis
ICD codes: M08.1, M45.6, M45.2, M45.3, M45.4, M45.5, M45.7
Drugs: sarilumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Diagnosis of AS according to the New York modified criteria

          -  Participants must had an adequate trial of at least 2 different Non-Steroidal
             Anti-Inflammatory Drugs (NSAIDs) taken for at least 2 weeks in each case and, on a
             stable dose for ≥2 weeks or be intolerant to NSAIDs

          -  Participants must had active AS for ≥3 months before screening and active disease must
             be present at screening and at baseline; Active AS being defined by:

               -  Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of ≥4
                  (Numerical Rating Scale 0-10)

               -  Total back pain score ≥4 (Numerical Rating Scale 0-10)

        Participants treated with corticosteroid must be on a stable dose for ≥2 weeks prior to
        baseline

        Participants treated with the Disease Modifying Anti-Rheumatic Drugs (DMARDs)
        hydroxychloroquine, sulfasalazine and methotrexate (MTX) must be on stable dose ≥12 weeks
        prior to baseline

        Exclusion criteria:

          -  <18 years old or ≥75 years old

          -  Complete fusion of the spine

          -  Past history of non response to any anti-Tumor Necrosis Factors (TNFs) treatment or
             non response to any other biological treatment for AS

          -  Any past or current treatment with anti-TNF's or any biological agent within 3 months
             prior to screening

          -  Treatment with DMARDs except for hydroxychloroquine, sulfasalazine and MTX

          -  MTX >25 mg/week

          -  hydroxychloroquine >400 mg/day

          -  Sulfasalazine >3 g/day

          -  Treatment with oral prednisone or equivalent corticosteroids >10 mg/day within 6 weeks
             prior to screening

          -  Use of intramuscular or intra-articular corticosteroids within the last 4 weeks before
             screening

          -  Previous treatment with cyclosporine, azathioprine

        The above information was not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT01469767 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: fluocinonide cream
SMILES: [H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female with mild to severe atopic dermatitis, 12 years of age or older, that
             agree to participate and provide written consent (parent permission and assent if
             applicable).

          -  Have an Investigator Global Assessment of mild to severe atopic dermatitis (IGA rating
             of 2 through 4 in the Investigator Global Assessment).

          -  Visual Analog Scale of Itch score at Baseline must be greater than or equal to 50 on a
             100-point scale.

          -  Percentage of overall body surface area of involvement (BSA) must be ≥2%.

          -  Women of childbearing potential will be allowed to participate in the study, and will
             be required to use at least one form of birth control.

        Exclusion Criteria:

          -  Use within four weeks from Baseline any systemic anti-inflammatory medication, which
             may influence study outcome, such as systemic corticosteroids.

          -  Application or use within two weeks of Baseline topical corticosteroid medications or
             topical anti-inflammatory medication, which may influence study outcome.

          -  Presence of a concurrent medical condition, which is determined by the investigator to
             potentially interfere with study outcomes or patient assessments.

          -  Introduction of any other prescription medication, topical or systemic, for atopic
             dermatitis while participating in the study.

          -  Use of anti-histamines while participating in the study will not be permitted unless
             the subject meets criteria for anti-histamine use on the VAS scale. Additionally, the
             subject must remain on a stable dose of anti-histamine throughout the study period. If
             a patient meets such criteria for anti-histamine use, this will be noted in the
             subject's chart.

          -  Amount of disease involvement that would require >60 gm of cream in a 1 week period.

          -  Subjects with known allergy or sensitivity to topical Vanos® cream or components.

          -  Pregnant women

          -  Women who are breastfeeding
Clinical trial NCT00313248 (phase 2, status: completed)
Conditions: breast neoplasm
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: sagopilone (zk 219477), sagopilone (zk 219477)
SMILES: C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1, C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic breast cancer (meaning the cancer has spread beyond its original location)

          -  At least one measurable lesion by CT or MRI

          -  Progression of disease following previous therapy for breast cancer

          -  Have received previous treatment with anthracyclines (e.g. doxorubicin[Adriamycin or
             Doxil] or epirubicin [Ellence]), taxanes (paclitaxel [Taxol or Abraxane] or docetaxel
             [taxotere]) for your breast cancer

          -  Not be pregnant

          -  Additional criteria to be determined at screening visit.

        Exclusion Criteria:

          -  More than 3 previous chemotherapy regimens

          -  More than one treatment with non cytotoxic agents for breast cancer therapy (e.g.
             herceptin [trastuzumab] or Avastin [bevacizumab)

          -  Prior treatment with epothilones (e.g. Ixabepilone)

          -  Symptomatic brain metastases

          -  Additional criteria to be determined at screening visit
Clinical trial NCT00409006 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed, cisplatin, gefitinib
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic or cytologic diagnosis non-small cell lung cancer (NSCLC) (Stage IIIB or
             IV)

          -  Have not received any prior chemotherapy, molecular therapy, immunotherapy, biological
             therapy, or radiotherapy. Exception: palliative radiotherapy that is completed at
             least 4 weeks prior to study enrolment.

          -  Have 'never smoked' (defined as having smoked <100 cigarettes during his/her lifetime)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

        Exclusion Criteria:

          -  Concurrent administration of any other tumor therapy

          -  Other co-existing malignancies

          -  Pregnancy or breast feeding

          -  Serious concomitant disorders

          -  Inability or unwillingness to take folic acid or vitamin B12 supplementation
Clinical trial NCT00168155 (phase 2, status: completed)
Conditions: colorectal adenocarcinoma, liver metastases
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: perioperative chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  stage IV colorectal cancer isolated to the liver

          -  one measurable lesion

          -  metastases are completely resectable or amenable to ablation

          -  Karnofsky >70

          -  Adequate bone marrow function

          -  adequate hepatic function

          -  adequate renal function

          -  informed consent

        Exclusion Criteria:

          -  primary tumor not controlled by locoregional treatments

          -  bilateral portal vein and/or hepatic artery involvement

          -  previous chemotherapy directed at treatment of metastatic colorectal cancer

          -  underlying acute or chronic liver disease

          -  Gilbert's disease

          -  patients receiving phenytoin or phenobarbital prophylaxis

          -  presence of any concurrent medical or psychiatric condition that serves as a
             contraindication to surgery or chemotherapy

          -  pregnancy

          -  malignancy other than basal cell or squamous cell carcinoma of the skin within the
             preceding 5 years

          -  use of another investigational medication concurrently or within 4 months of
             enrollment
Clinical trial NCT02467010 (phase 2, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: bortezomib, cyclophosphamide, dexamethasone
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Stage II-III Multiple Myeloma

          -  Relapse or primary refractory disease after initial chemotherapy

          -  WHO performance status 0 - 2

          -  Life expectancy of at least 6 weeks

          -  ANC (absolute neutrophil count) ≥ 1.0x109/l(or ≥ 0.5x109/l, if due to bone marrow
             infiltration by malignancy)

          -  Platelet count ≥ 75x109/l or ≥ 50x109/l, if due to bone marrow infiltration by
             malignancy)

          -  Written informed consent (present in patient's file)

          -  Patient is able and willing to use adequate contraception during therapy and for at
             least 1 month after study

          -  Patient has the ability to understand the requirements of the study

        Exclusion Criteria:

          -  Previous treatment with bortezomib

          -  Urine production < 1.5 l/24h

          -  Pre-existent polyneuropathy (grade 2 or higher, according to CTCAE 3.0)

          -  Pregnancy or positive pregnancy tests during study and for 1 month after final dose of
             thalidomide

          -  History of active malignancy during the past 5 years with the exception of basal
             carcinoma of the skin)

          -  Active uncontrolled infections

          -  Additional uncontrolled serious medical or psychiatric illness
Clinical trial NCT01077726 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: capecitabine [xeloda]
SMILES: CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  female patients, >=18 years of age;

          -  breast cancer;

          -  CNS progression after radio-surgery + whole brain radiotherapy, or whole brain
             radiotherapy alone;

          -  at least one measurable lesion;

          -  ECOG performance status 0-2.

        Exclusion Criteria:

          -  prior systemic treatment of brain metastases;

          -  prior disease progression while on Xeloda treatment;

          -  previous history of cancer (other than curatively treated basal and squamous cell
             cancer of the skin or in situ cancer of the cervix) in previous 5 years;

          -  clinically significant cardiovascular disease.
Clinical trial NCT00208975 (phase 2, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: mitoxantrone/cyclophosphamide, fludarabine, rituximab and gm-csf
SMILES: NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  To qualify for this study, the patient must have relapsed, refractory or previously
             untreated low-grade (indolent) non-Hodgkin lymphoma of the following subtypes:
             Follicular center cell lymphoma grade 1, lymphoplasmacytoid lymphoma, small
             lymphocytic lymphoma, splenic marginal-zone types lymphoma, monocytoid B-cell lymphoma
             and extranodal mucosa-associated lymphoid tissue (MALT) lymphomas. Final eligibility
             will be determined by the health professionals conducting this clinical trial.

        Exclusion Criteria:

          -  Patients who have received prior treatment with purine analogs will be excluded from
             this study. Also, patients whose diagnostic/histologic subtype cannot be confirmed by
             our institution will not be able to participate in this study. Final eligibility will
             be determined by the health professionals conducting this clinical trial.
Clinical trial NCT00453193 (phase 2, status: terminated)
Conditions: lymphoma, leukemia
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: pentostatin, alemtuzumab
SMILES: OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1N=CNC[C@H]2O, N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    slow accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Age 18 years and older

          2. Diagnosis of T lymphoid malignancy established by peripheral blood, bone marrow or
             tissue (skin, lymph node or other) examination and using the standard criteria.

          3. Patients with untreated T-cell-prolymphocytic leukemia (T-PLL), peripheral T-cell
             lymphoma, hepatosplenic T-cell lymphoma and NK/T cell lymphoma are eligible.

          4. Patients with relapsed/refractory T-PLL, T-lineage acute lymphoblastic leukemia
             (T-ALL), Adult T-cell leukemia/lymphoma (ATLL), peripheral T-cell lymphoma,
             hepatosplenic T-cell lymphoma and NK/T cell lymphoma and other T-lymphoid malignancies
             are eligible. Patients who have had prior therapy with either alemtuzumab or
             pentostatin as single agents are eligible.

          5. Willing to use adequate contraception for the entire duration of the study.

          6. Performance status 0-2.

          7. Creatinine less than or equal to 2.0 mg/dL and calculated creatinine clearance greater
             than 40

          8. Bilirubin less than or equal to 3.0 mg/dL, transaminases (aminotransferase (AST or
             SGOT) and alanine aminotransferase (ALT or SGPT)) less than 4 x upper limit of normal
             unless related to the disease.

          9. Left ventricular ejection fraction greater than 30%.

        Exclusion Criteria:

          1. Unable or unwilling to sign the consent form.

          2. Pregnant or lactating

          3. Known to be HIV+

          4. Active and uncontrolled infection as judged by treating physician
Clinical trial NCT01094067 (phase 2, status: terminated)
Conditions: pulmonary arterial hypertension
ICD codes: I27.21
Drugs: act-050089
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=NC=C(C=C2)C(C)C)N=C(N=C1OCCO)C1=CC(=NC=C1)C1=NNN=N1
Reason stopped: 
    due to slow recruitment, the study was prematurely discontinued.
  
Eligibility criteria:

        Inclusion Criteria :

          1. Signed informed consent prior to initiation of any study-mandated procedure

          2. Male and female patients 18 years of age or older

          3. Patients with PAH according to one of the following subgroups of the Dana Point
             Classification Group 1:

               -  Idiopathic, or

               -  Heritable, or

               -  Associated with connective tissue disease

          4. Documented hemodynamic diagnosis of PAH by right heart catheterization (not part of
             study mandated procedures):

               -  Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and

               -  Resting mean pulmonary vascular resistance (PVR) ≥ 240 dyn•s•cm 5 and

               -  Pulmonary capillary wedge pressure ≤ 15 mmHg

          5. Modified NYHA functional class II-III

          6. Patients on treatment with ERAs, PDE-5 inhibitors or a combination of both, if used
             for at least 3 months prior to Visit 1 and dosing kept stable for at least 28 days
             prior to Visit 1.

        Exclusion Criteria :

          1. Patients with PAH in Dana Point Classification Groups 2-5, and PAH Group 1 subgroups
             not covered by inclusion criterion No. 3

          2. Patients with sitting SBP < 100 mmHg

          3. Patients with sitting DBP < 60 mmHg

          4. Patients with body weight < 50 kg (110 lbs)

          5. Patients with clinically significantly elevated liver enzymes (AST, ALT and/or
             alkaline phosphatase > 3 times upper limit)

          6. Patients with clinically significant chronic renal insufficiency (serum creatinine
             >2.5mg/dL / 221 µmol/L)

          7. Patients with moderate or severe hepatic impairment (Child-Pugh B and C)

          8. Patients who have received prostacyclin (epoprostenol) or prostacyclin analogs (e.g.,
             treprostinil, iloprost and beraprost) within 28 days of Visit 1

          9. Patients who have received any investigational drugs within 28 days of Visit 1

         10. Patients who have received cyclosporine A (CsA) or tacrolimus within 28 days of Visit
             1

         11. Psychotic, addictive or other disorder limiting the ability to provide informed
             consent or to comply with the study

         12. Life expectancy less than 12 months

         13. Females who are lactating or pregnant (positive pre-treatment pregnancy tests) (serum
             test at Screening and urine test on Visit 1 and 2) or females who are not using a
             reliable method of birth control (failure rate less than 1% per year) during the study
             and for at least one month after last administration of study drug

         14. Known hypersensitivity to any of the excipients of the drug formulation.
Clinical trial NCT00209092 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel, capecitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed breast carcinoma.

          -  Early stage breast cancer (stage 1, 2, 3).

          -  No evidence of disease outside the breast or chest wall, except ipsilateral axillary
             lymph nodes.

          -  18 years of age or older.

          -  Final eligibility for a clinical trial is determined by the health professionals
             conducting the trial.

        Exclusion Criteria:

          -  Prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast
             cancer.

          -  Major surgery within 28 days of study entry.

          -  Evidence of central nervous system (CNS) metastases.

          -  Final eligibility for a clinical trial is determined by the health professionals
             conducting the trial.
Clinical trial NCT01319019 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: gsk961081, salmeterol, placebo
SMILES: OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatient Subjects

          -  Subjects who give their signed and dated informed consent to participate

          -  40 or more years of age, inclusive, at Visit 1

          -  Male or females

          -  Subjects with an established clinical history of COPD

          -  Current or previous cigarette smokers with a history of ≥ 10 pack-years of cigarette
             smoking

          -  Subjects with the following liver function test values:

          -  Subjects with a measured post-salbutamol FEV1/FVC ratio of < 0.70 at Visit 1
             (Screening).

          -  Subjects with a measured post-salbutamol FEV1 30-70% of predicted normal values

        Exclusion Criteria:

          -  Women who are pregnant or lactating or are planning to become pregnant during the
             study.

          -  Current diagnosis of asthma

          -  Other significant respiratory disorders besides COPD, including alpha-1 deficiency

          -  Previous lung resection surgery

          -  Significant abnormalities in chest x-ray presentation

          -  Hospitalization for a COPD exacerbation within 12 weeks prior screening

          -  Use of oral corticosteroids or antibiotics for COPD or antibiotics for a lower
             respiratory tract infection within 6 weeks

          -  Any significant disease that would put subject at risk through study participation

          -  BMI greater than 35

          -  Pacemaker

          -  Significantly abnormal ECG, clinical lab finding (including Hepatitis B or C)

          -  Cancer

          -  Allergy or hypersensitivity to beta adrenergic receptor-agonist, sympathomimetic,
             anticholinergic/anti-muscarinic receptor antagonist, or inhaler excipients

          -  Diseases that would contra-indicate the use of anticholinergics

          -  Use of sysemic corticosteroids within 6 weeks of screening

          -  Use of long-acting beta-agonists within 48 hours of screening

          -  Use of tiotropium within 7 days of screening

          -  Use of theophyllines or anti-leukotrienes within 48 hours of screening

          -  Use of short-acting bronchodilators within 4 hours of screening

          -  Use of investigational medicines within 30 days of screening

          -  Use of high dose inhaled corticosteroids

          -  Use of long-term oxygen therapy, CPAP or NIPPV

          -  Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks
             prior to Visit 1

          -  Regular (q.i.d or greater) use of short acting bronchodilators, including nebulized
             therapy

          -  Affiliation with Investigator Site

          -  Questionable Validity of Consent

          -  Previous use of GSK961081